Remedy Pharmaceuticals Issues First Quarter 2016 Report
NEW YORK, New York, April 6, 2016 — Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving hospital-based treatment to people affected by central nervous system related edema, today announced that the Company issued an end-of-first-quarter report.
Highlights of the report include six-month data from its Phase 2 randomized, double blind trial of the drug CIRARA™ in large hemispheric infarctions, adjudicated neurological mortality findings, and results of an analysis on patients 70 and younger.
The report may be downloaded at http://www.remedypharmaceuticals.com/investor-information.html
Cerebral edema (swelling) can result from brain trauma or from non-traumatic causes.. The brain is especially susceptible to injury from edema because it is located within a confined space and cannot expand. If not treated, cerebral edema may cause permanent disability or death. In the Company’s phase 2 study, GAMES-RP, edema caused almost 60% of deaths in the placebo arm.
CIRARA is a patented, high affinity inhibitor of Sur1-Trpm4 channels, which are upregulated following ischemia and trauma. Opening of these channels can lead to damage and death of the blood brain barrier, and subsequent edema. Sur1-Trpm4 channels were discovered by University of Maryland neurosurgeon Dr. J. Marc Simard, scientific founder and board member of Remedy Pharmaceuticals.
CIRARA is suitable for intravenous delivery at the bedside or even in an ambulance. CIRARA uses our proprietary, patented MPD™ technology. CIRARA is an investigational drug and is not approved by FDA.
ABOUT REMEDY PHARMACEUTICALS
Remedy Pharmaceuticals, Inc. is a privately-held, clinical stage pharmaceutical company focused on developing and bringing lifesaving treatment to millions of people affected by acute central nervous system (CNS) edema – including large hemispheric infarction, traumatic brain injury, spinal cord injury, as well as other ischemic injuries and neurological disorders.
212-586-2226 x 225